A New Generation of Precision Medicines

Angis Bio uses biology to drive advanced computational design.

Angis Bio is developing a new era of precision medicines where “Biology drives Innovation.” Our “Small Format Proteins (SFPs)” and Small Format Antibodies (SFAs)” are therapeutics derived from our high diversity, randomized display libraries. Angis Bio has integrated computational and bioinformatic analysis to its biology-based drug discovery paradigm. The goal is to “accelerate” the time from discovery to moving its drug leads into formal preclinical development

what we do

Why Angis is Exceptional

Angis has an exquisite approach for analyzing protein:protein interactions and identifying the pharmacologically active sites on proteins called HotSpots.

The diversity, randomness and size of our display libraries give us a unique capability to differentiate only those HotSpots relevant to disease which allows us to rapidly develop and validate either agonist or antagonist drug leads for any disease target.

We integrate bioinformatic analysis into our drug discovery platform to identify novel targets as well to determine if a target is “druggable”. In addition, we use a computational approach to “improve” our therapeutic candidates and validate those leads which bind to critical HotSpots on the target.

Finally, we can rapidly identify novel internalizing SFPs and SFAs which can be used to develop drug conjugates (SFDC: Small Format Drug Conjugates) for treating cancer and other disease indications

Precise & Versatile

Small Format Proteins (SFPs) and Antibodies (SFAs)

Angis Bio is developing target-specific SFPs and SFAs that are a diverse group of protein scaffolds characterized by small (2–15 kDa) size, stability and versatility for use as therapeutics in a variety of disease indications.

These leads are derived from high diversity display libraries. In the case of SFPs, the libraries consist of either 20 or 40 amino acids where the sequences are completely randomized to eliminate “bias”. SFAs are fully human single domain antibodies derived from germline heavy or light chains. Here, each of the CDRs are completely random and the framework derived from human germline genes. As a result, the antigen binding regions have sequences outside the normal human repertoire thereby expanding the number of target-specific binders.

Protein-Protein Interaction Hotspots

SFPs and SFAs define the critical Hotspots involved in protein-protein interactions

Differentiate Disease Hotspots

SFPs and SFAs can differentiate Hotspots relevant to disease

Target-Specificity

SFPs and SFAs show exquisite target-specificity and can distinguish a single amino acid change

Agonists or Antagonists

SFPs and SFAs can have biological activity as agonists or antagonists

Unique Hotspot Approach

The Angis Bio Difference

Our combination of wet lab design and computational bioinformatics gives us an exquisite approach for analyzing protein:protein interactions to identify pharmacologically active sites on proteins or “HotSpots”.

Method for Rapid, Validated Drug Leads

Precise differentiation of those HotSpots relevant to disease and rapidly develop validated drug leads.

Proprietary Biological Therapeutics

Angis Bio uses multiple interconnected technologies and platforms which involve the interaction of high diversity, randomized SFP and SFA libraries

Unique Composition of Matter

Generation of novel composition of matter which, in the case of the SFA libraries, lies outside the normal human antibody repertoire.

Rapid Molecular Identification

Immediate generation of novel composition of matter which, in the case of the PoA libraries, lie outside the normal human repertoire.

A Multifunctional Platform to Innovative Biologics

The Company believes its innovative SFPs and SFAs have broad versatility and application. The Company’s technology foundation has five distinct but interconnected categories and can offer multifunctional opportunities, all being underpinned by the Company’s proprietary display libraries.

A New Generation of Biologics for Cancer & Many Other Diseases
Next Generation Drug Targeting.
Targeted Bispecific and Bifunctional Therapeutics
First in-Class Potential for use in novel CAR-T approaches including solid tumors
Small Format Drug Conjugates.

Pocket Biologics

A Multifunctional Platform to Innovative Biologics

The Company believes its innovative Pocket Biologics have broad versatility and application. The Company’s technology foundation has five distinct but interconnected categories and can offer multifunctional opportunities, all being underpinned by the Company’s Pocket Biologics:

A New Generation of Biologics for Cancer & many other diseases

Next Generation Drug Targeting

Targeted Bispecific and Bifunctional Therapeutics – First in-Class

Potential for use in novel CAR-T approaches including solid tumors

Pocket-Drug Conjugates

Target Specific Leads

Target Validation

Targeted Bi-Specifics

Pocket-Drug Conjugates

CAR-T Applications

PoBs

who we are

Our Management Team

Neil Goldstein, Ph.D., President and Chief Scientific Officer

Dr. Goldstein is equipped with a unique blend of scientific expertise and management/business acumen.

He has more than 50+ years of experience as an academic scientist, research scientist, and manager within both start-up and established companies in the pharmaceutical and biotechnology industries. As a result, He has experience leveraging his knowledge of molecular biology, immunology, and drug discovery to identify new areas applicable to the diagnosis and treatment of disease. Dr. Goldstein has co-authored 70+ publications in peer-reviewed journals and books, numerous abstracts, and was a co-inventor on 15 issued patents; He has contributed to the development of 3 drugs that are currently on the market or in human clinical trials and has developed several preclinical drug leads for oncology, autoimmunity, and immunological deficiencies. Dr. Goldstein received his PhD in Microbiology from the Waksman Institute of Immunology at Rutgers University and did his postdoctoral work at the Wistar Institute.

John Prendergast, Ph.D., CEO and Chairman

Dr. Prendergast is co-founder of Palatin Technologies, a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.

He has been chairman of the board at Palatin since June 2000 and director since August 1996. Dr. Prendergast is also president of Summercloud Bay, an independent consulting firm providing services to the biotechnology industry, and director and executive board chairman of Antyra, a privately-held biopharmaceutical firm. From 1991 through 1997, he was managing director of The Castle Group Ltd., a medical venture capital firm. Dr. Prendergast received his M.Sc. and Ph.D. from the University of New South Wales, and a C.S.S. in administration and management from Harvard University.

A New Generation of Precision Medicines

Angis Bio uses biology to drive advanced computational design.

what we do

Why Angis is Exceptional

Precise & Versatile